2-Pyrimidinamine, N-(4-nitrophenyl)-4-(2-phenyl-5-oxazolyl)- | 647030-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Pyrimidinamine, N-(4-nitrophenyl)-4-(2-phenyl-5-oxazolyl)-
• 英文别名: N-(4-nitrophenyl)-4-(2-phenyl-1,3-oxazol-5-yl)pyrimidin-2-amine
• CAS: 647030-93-1
• 化学式: C₁₉H₁₃N₅O₃
• 分子量: 359.344
• InChiKey: FUVQUXGDVCMYJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Therapeutic Methods For Type I Diabetes
  申请人：Davis Roger J.

  公开号：US20120208846A1

  公开（公告）日：2012-08-16

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
• Therapeutic Methods for Type I Diabetes
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US20150313881A1

  公开（公告）日：2015-11-05

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
• US7897572B1
  申请人：——

  公开号：US7897572B1

  公开（公告）日：2011-03-01
• US8501812B2
  申请人：——

  公开号：US8501812B2

  公开（公告）日：2013-08-06
• [EN] THERAPEUTIC METHODS FOR TYPE I DIABETES<br/>[FR] PROCEDES THERAPEUTIQUES POUR LE DIABETE DE TYPE I
  申请人：UNIV MASSACHUSETTS MEDICAL

  公开号：WO2006104983A1

  公开（公告）日：2006-10-05

  [EN] The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ß-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
  [FR] La présente invention se rapporte au traitement et à la prévention du diabète de type I. Plus spécifiquement, l'invention se rapporte à des composés qui traitent ou qui évitent la destruction par le système immunitaire de l'organisme des cellules ß (c'est-à-dire des cellules productrices de l'insuline dans les îlots de Langerhans du pancréas) grâce à l'inhibition de JNK2, à l'inhibition sélective de JNK2 ou à l'inhibition de l'expression du gène MAPK9 ou du produit de ce gène. Dans un mode de réalisation, la présente invention envisage le diagnostic, l'identification, la production et l'utilisation de composés qui modulent l'expression du gène MAPK9 ou l'activité du produit du gène MAPK9 y compris, mais sans limitation, JNK2, l'acide nucléique qui code pour MAPK9 et des homologues, des analogues et des délétions de ceux-ci, de même que des molécules anti-sens, des ribozymes, des molécules à triple hélice, des anticorps et des polypeptides ainsi que de petites molécules inorganiques. La présente invention envisage diverses formulations pharmaceutiques et les voies d'administration pour de tels composés.